Compare Novavax Inc (NVAX) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Novavax Inc trades at $12.94 (market cap $1.82B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $214.24 (market cap $39.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 21.5× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days on average.
| NVAX | TTWO | |
|---|---|---|
Market Cap | $1.82B | $39.15B |
Volume | 6,198,505 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $12.56 | $262.29 |
52-Week Low | $6.22 | $189.69 |
Typical Hold Time | 59 Days | 111 Days |
Enterprise Value | $1.39B | $40.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Take-Two Interactive (TTWO) trades at $213.88, up 4.84% with bullish technical signals and strong analyst support. The company shows mixed fundamentals with revenue growth to $5.63B but negative net income of -$4.48B, though recent earnings beats and the upcoming GTA VI launch provide optimism. Technical indicators show the stock trading near resistance at $215 with RSI suggesting potential overbought conditions.
The outlook remains positive driven by GTA VI's November launch, with analysts projecting 37% upside to $292.30 consensus target. Key risks include persistent profitability challenges, high debt levels, and execution pressure on major game releases. Institutional ownership trends show continued confidence despite recent financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
